January 2008
Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p4
Trade Publication
The article reports on a license and distribution agreement signed between Oasmia Pharmaceutical and Orion Corp. The agreement covers the marketing and sales of the human cancer drug Paclical ® or micellar paclitaxel in the Nordic region. The drug is under Phase III development by the company, with ovarian cancer as the target indication.


Related Articles

  • Abbott, Oasmia ink deal.  // DVM: The Newsmagazine of Veterinary Medicine;Aug2009, Vol. 40 Issue 8, p17 

    The article reports on the finalization of the multi-year agreement between Abbott Laboratories Inc. and Oasmia Pharmaceutical AB to market the Paccal Vet, a chemotherapeutic agent for dogs in the U.S. and Canada. It mentions that the deal gives Abbott the exclusive rights to distribute the drug...

  • NeoPharm regains rights to cancer drugs.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p15 

    Reports that NeoPharm will seek U.S. approval for a unique formulation of paclitaxel after the biotechnology firm regained commercialization rights to investigational cancer drugs previously licensed to Pfizer. Efforts of NeoPharm to terminate its license agreement with Pfizer since 2002; Plan...

  • Biotech-Biotech Collaborations: Modified And Terminated Agreements: July 1 - August 25, 2011.  // BioWorld Insight;8/29/2011, Vol. 19 Issue 35, p18 

    A table is presented which shows terminated and modified agreements on collaborations of several biotechnology firms including Oasmia Pharmaceutical AB, Isconova AB, and Galapagos NV from July 1 to August 25, 2011.

  • Combination therapy doubles PSA response rate. Carlson, Robert H. // Urology Times;Aug2001, Vol. 29 Issue 8, p20 

    Reports the use of paclitaxel plus estramustine phosphate in treating men with prostate cancer in the research conducted at the United States Oncology Network in Houston, Texas. Confirmation of the increase of PSA response rate; Trial conducted on sixty three community site in nineteen U.S....

  • Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery. Ajay Gautam; Nadezhda Koshkina // Current Cancer Drug Targets;Aug2003, Vol. 3 Issue 4, p287 

    Paclitaxel (PTX, Taxol) has revolutionized cancer treatment in the past decade and is recognized as one of the biggest advances in oncology medicine. In spite of the good clinical efficacy shown by PTX, there is still a growing need to achieve better safety and pharmacokinetic profile of PTX in...

  • Trebananib, paclitaxel extend PFS in ovarian cancer.  // Hem/Onc Today;8/25/2013, Vol. 14 Issue 16, p53 

    The article reports on the results of the phase 3 TRINOVA-1 study which found that adding trebananib to paclitaxel improved progression free survival (PFS) in patients with recurrent ovarian cancer compared with paclitaxel alone.

  • Three more drugs included in Cancer Drugs Fund.  // PharmacoEconomics & Outcomes News;Mar2014, Vol. 699 Issue 1, p12 

    The article reports on the addition of paclitaxel, bevacizumab and cabozantinib to the Cancer Drugs Fund (CDF) of England in 2014.

  • Weekly 1 Hour Paclitaxel Infusion in Patients with Recurrent Gynecological Tumors: a Pilot Study. Ota, Shunichiro; Sugiyama, Toru; Komai, Kan; Hirai, Nobuyuki; Kumagai, Seisuke; Ushijima, Kimio; Nishida, Takashi; Kamura, Toshiharu // Japanese Journal of Clinical Oncology;Aug2001, Vol. 31 Issue 8, p395 

    Background: Intensifying the dose of paclitaxel given in a weekly schedule is useful towards improving the therapeutic index of paclitaxel in treating a variety of advanced and recurrent malignancies and is suitable for outpatient administration. This pilot study was carried out to evaluate the...

  • Paclitaxel.  // Reactions Weekly;Oct2015, Vol. 1574 Issue 1, p202 

    The article presents a case study of a 72-year-old woman who developed photosensitivity during a weekly treatment with paclitaxel for breast cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics